 | |
| Names | |
|---|---|
| IUPAC name 5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl-N-[3-(1-methylpiperidin-4-yl)propyl]pyrimidin-2-amine | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| KEGG | |
| UNII | |
| |
| |
| Properties | |
| C23H32N6 | |
| Molar mass | 392.551 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Toreforant (JNJ-38518168) is an orally-dosed selectiveantagonist of thehistamine H4 receptor that has been studied for various health conditions. It is the successor of a number of H4-selective compounds developed byJohnson & Johnson.[1] Phase IIa clinical trials completed as recently as November 2018 continue to suggest that toreforant is safe.[2]
As of the end of 2020, there is no regulator-approved H4 antagonist. In U.S. Phase II clinical trials, toreforant, by itself, did not show efficacy againsteosinophilic asthma.[2] The drug did show at least partial efficacy againstrheumatoid arthritis in patients who were nonresponsive tomethotrexate.[3] As the H4 receptor is widely implicated in the regulation of inflammatory states, the potential uses for an H4 antagonist remain significant.[4][5][6]
 | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |
